Randomized trial of paroxetine in end-stage COPD

Monaldi Archives for Chest Disease - Pulmonary Series

Volumn 61, Issue 3, 2004, Pages 140-147

  Lacasse, Yves ^a   Beaudoin, L ^b   Rousseau, L ^a   Maltais, F ^a  

^a LAVAL UNIVERSITY   (Canada)

^b Service Regional Soins Respiratoires   (Canada)

Author keywords

Antidepressant drug; COPD; Depression; Paroxetine; Randomized trial

Indexed keywords

ANTIDEPRESSANT AGENT; OXYGEN; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DISEASE EXACERBATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DYSPNEA; FATIGUE; FEMALE; FLATULENCE; GERIATRIC DEPRESSION SCALE; HEADACHE; HEALTH SURVEY; HUMAN; MALE; MORBIDITY; NAUSEA; OXYGEN THERAPY; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SOMNOLENCE; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; TASTE AVERSION; TREATMENT OUTCOME; TREMOR; XEROSTOMIA;

EID: 12344305572     PISSN: 11220643     EISSN: 2465101X     Source Type: Journal    
DOI: 10.4081/monaldi.2004.692     Document Type: Article

References (33)

1. Lacasse Y, Brooks D, Goldstein RS. Trends in the epidemiology of chronic obstructive pulmonary disease in Canada, 1980-95. Chest 1999; 116: 306-13.
2. Cooper CB. Determining the role of exercise in patients with chronic pulmonary disease. Med Sci Sports Exer 1995; 27: 147-57.
3. Lacasse Y, Rousseau L, Maltais F. Prevalence of depressive symptoms and depression in patients with severe oxygen-dependent chronic obstructive pulmonary disease. J Cardiopulm Rehabil 2001; 21: 80-6.
4. American Thoracic Society. Pulmonary rehabilitation - 1999. Am J Respir Crit Care Med 1999; 159: 1666-82.
5. Casaburi R, Patessio A, Ioli F, et al. Reductions in exercise lactic acidosis and ventilation as a result of exercise training in patients with obstructive lung disease. Am Rev Respir Dis 1991; 143: 9-18.
6. Maltais F, LeBlanc P, Simard C, et al. Skeletal muscle adaptation to endurance training in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996; 154: 442-7.
7. Lacasse Y, Brosseau L, Milne S, et al. Respiratory rehabilitation in chronic obstructive pulmonary disease (Cochrane review). In: the Cochrane Library, Issue 2, 2002. Oxford: Update Software.
8. Brooks D, Lacasse Y, Goldstein RS. Pulmonary rehabilitation programs in Canada: national survey. Can Respir J 1999; 6: 55-63.
9. Yesavage JA, Brink TL. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiat Res 1983; 17: 37-49.
10. Brink TL, Yesavage JA, Lum O, et al. Screening tests for geriatric depression. Clin Gerontologist 1982; 1: 37-43.
11. Yesavage JA. Depression in the elderly. Postgrad Med 1992; 91: 255-61.
12. Covino NA, Dirks JF, Kinsman RA, et al. Patterns of depression in chronic illness. Psychother Psychosom 1982; 37: 144-53.
13. Gunasekara NS, Noble S, Benfield P. Paroxetine: an update of its pharmacology and therapeutic use in depression and a review of its use in other disorders. Drugs 1998; 55: 85-120.
14. Guyatt GH, Berman LB, Townsend M, et al. A measure of quality of life for clinical trials in chronic lung disease. Thorax 1987; 42: 773-8.
15. Lacasse Y, Wong E, Guyatt GH. A systematic overview of the measurement properties of the Chronic Respiratory Questionnaire. Can Respir J 1997; 4: 131-9.
16. Jaeschke R, Singer J, Guyatt GH. Measurement of health status: ascertaining the minimal clinically important difference. Controlled Clin Trials 1989; 10: 407-15.
17. McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-item short form health survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993; 31: 247-63.
18. Leplege A, Ecosse E, Verdier A, et al. The French SF-36 Health Survey: translation, cultural adaptation and preliminary psychometric evaluation. J Clin Epidemiol 1998; 51: 1013-23.
19. Lacasse Y, Guyatt GH. Methodology of therapeutic trials in COPD. In: Similowski T, Whitelaw WA, Derenne JP (eds.). Clinical management of chronic obstructive pulmonary disease. New York, Marcel Dekker Inc. 2002; 255-85.
20. Hopman WM, Towheed T, Anastassiades T, et al. Canadian normative data for the SF-36 health survey. Can Med Assoc J 2000; 163: 265-71.
21. Redelmeier DA, Tan SH, Booth GL. The treatment of unrelated disorders in patients with chronic medical diseases. N Engl J Med 1998; 338: 1516-20.
22. Ross S, Grand A, Counsell C, Gillespie W, Russell I, Prescott R. Barriers to participation in randomised controlled trials: a systematic review. J Clin Epidemiol 1999; 52: 1143-56.
23. American Psychiatric Association. Diagnostic and statistical manual of mental disorders IV. Washington DC, American Psychiatric Association, 1994.
24. Regier DA, Kaelber CT, Rae DS, et al. Limitations of diagnostic criteria and assessment instruments for mental disorders. Inmplications for research and policy. Arch Gen Psychiatry 1998; 55: 109-15.
25. Sullivan M, LaCroix A, Russo J, Swords E, Sornson M, Katon W. Depression in coronary heart disease: what is the appropriate diagnostic threshold? Psychosomatics 1999; 40: 286-92.
26. Gordon GH, Michiels TM, Mahutte CK, et al. Effect of Desipramine on control of ventilation and depression scores in patients with severe chronic obstructive pulmonary disease. Psych Res 1985; 15: 25-32.
27. Light RW, Merrill EJ, Despars J, et al. Doxepin treatment of depressed patients with chronic obstructive pulmonary disease. Arch Intern Med 1986; 146: 1377-80.
28. Borson S, McDonald GJ, Gayle T, et al. Improvement in mood, physical symptoms, and function with nortriptyline for depression in patients with chronic obstructive pulmonary disease. Psychosomatics 1992; 33: 190-201.
29. Ström K, Boman G, Pehrsson K, et al. Effect of proptyline, 10 mg daily, on chronic hypoxaemia in chronic obstructive pulmonary disease. Eur Respir J 1995; 8: 425-9.
30. Lacasse Y, Wong E, Guyatt GH, Goldstein RS. Health-status measure instruments in chronic obstructive pulmonary disease. Can Respir J 1997; 4: 152-64.
31. Steen SN. The effects of psychotropic drugs on respiration. Pharm Ther 1976; 2: 717-41.
32. Warrington SJ, Lewis Y. Cardiovascular effects of antidepressants: studies of Paroxetine in healthy men and depressed patients. Int Clin Psychopharmacol 1992; 6 [suppl.]: 59-64.
33. Nault D, Siok MA, Borycki E, Melanson D, Rousseau L, Lacasse Y. Psychosocial considerations in COPD. In: Bourbeau J, Nault D, Borycki E (eds.). Comprehensive management of chronic obstructive pulmonary disease. Hamilton, BC Decker Inc, 2002: 215-44.